Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.56 |
| ▸ | CDK1 | P06493 | 5/20 | 0.56 |
| ▸ | CCNB1 | P14635 | 5/20 | 0.56 |
| ▸ | CDK2 | P24941 | 4/20 | 0.56 |
| ▸ | CDK4 | P11802 | 3/20 | 0.56 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.56 |
| ▸ | CCND1 | P24385 | 3/20 | 0.56 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.48 |
| ▸ | CCND3 | P30281 | 1/20 | 0.48 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.48 |
| ▸ | EIF2AK2 | P19525 | 2/20 | 0.47 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.47 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.47 |
| ▸ | RET | P07949 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL91484 | 0.98 | CTSK (0.60) | CTSKKDM4EGAAHRH4CDK1 | |
| SCHEMBL91469 | 0.93 | CTSK (0.49) | CTSKKDM4EGAAHRH4CDK1 | |
| SCHEMBL15830033 | 0.85 | MAPK1 (0.62) | HRH4RETMAPK8MAPK9MKNK2 | |
| SCHEMBL6508763 | 0.85 | IKBKB (0.58) | CTSKHRH4CDK1CCNB1CDK2 | |
| SCHEMBL18677322 | 0.85 | CDK1 (0.54) | CTSKHRH4CDK1CCNB1CDK2 | |
| SCHEMBL24065221 | 0.85 | CDK1 (0.54) | CTSKHRH4CDK1CCNB1CDK2 | |
| SCHEMBL12367075 | 0.83 | IKBKB (0.61) | HRH4CDK1CCNB1CDK2CDK4 | |
| SCHEMBL17151392 | 0.83 | MKNK1 (0.55) | CTSKHRH4CDK1CCNB1CDK2 | |
| SCHEMBL13693348 | 0.83 | BRD4 (0.52) | CDK1CCNB1CDK2CDK4CCNA2 | |
| SCHEMBL13524818 | 0.83 | BRD4 (0.52) | CDK1CCNB1CDK2CDK4CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865732-B2 | Heterocyclic compounds and uses thereof | NOVARTIS AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | NOVARTIS AG (CH) | 2013-08-15 | — | — | US | disclosed |
| US-8129394-B2 | Heteroaryl-substituted imidazole compounds and uses thereof | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-7696210-B2 | Gonadotropin releasing hormone receptor antagonists | WYETH (US) | 2010-04-13 | — | — | US | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
| EP-1377573-A2 | PYRAZOLOPYRIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2004-01-07 | — | — | EP | disclosed |
| WO-2002048148-A2 | PYRAZOLOPYRIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | BRAF, ARAF, KRAS | CTSK 1606/4885KDM4E 3041/4885GAA 2653/4885 |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | BRAF, RAF1, HRAS | CTSK 2315/4885KDM4E 2526/4885GAA 2568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.